Clinical Trial

Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty

Study acronym: RETAIN
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate whether the investigational drug PLG0206 can help reduce recurrence of infection in adults who have undergone total knee replacement and are receiving a DAIR (Debridement, Antibiotics, and Implant Retention) surgical procedure to treat a Prosthetic Joint Infection (PJI). The study will also assess the safety of PLG0206 when used as an irrigation solution during the DAIR procedure. Participants will receive either PLG0206 or a placebo (an inactive substance that looks like the investigational drug), in addition to standard of care treatments. All participants will be monitored for approximately one year following their DAIR procedure.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2025-10-03; most recent amendment 2026-07-01.
Status change: Not Yet Recruiting → Recruiting 2025-12-15
Trial Details
NCT Number NCT07214311
Lead Sponsor Peptilogics
Conditions Prosthetic-joint Infection
Enrollment 240 participants
Start Date 2026-02-03
Primary Completion 2028-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-04